Wright Medical Group, Inc. has announced that peer-reviewed data from a prospective, randomized, controlled, multi-center study has been published. The data confirms the effectiveness of the GRAFTJACKET Regenerative Matrix for the treatment of diabetic foot ulcers. This study, entitled “Clinical Effectiveness of an Acellular Dermal Regenerative Tissue Matrix Compared to Standard Wound Management in Healing Diabetic Foot Ulcers,” was led by David G. Armstrong, DPM, PhD, Professor of Surgery and Director, Southern Arizona Limb Salvage Alliance (SALSA) at the University of Arizona College of Medicine. The study included a total of 86 patients who were treated either with GRAFTJACKET Regenerative Matrix or the standard of care, which was the control group. Analysis at the study’s endpoint of 12 weeks confirmed complete wound healing was achieved in only 46% of the control group patients while 70% of patients who received a single application of the GRAFTJACKET Matrix achieved complete wound healing. This difference between groups was statistically significant. Additionally, GRAFTJACKET Matrix treated patients healed more quickly on average than the control group. Given the results of the study, patients treated with GRAFTJACKET Matrix are two times more likely to experience complete wound healing by 12 weeks versus patients treated with standard wound care. “The study supports the use of this technology as a clinically and potentially cost-effective modality for the treatment of complex diabetic foot ulcers,” notes Dr. Armstrong, principal investigator for the study. “By improving our ability to successfully treat and heal diabetic foot ulcers, we also reduce the risk of a lower limb amputation, a procedure that carries significant social and financial costs and dramatic quality of life implications.” “The results of this study further prove GRAFTJACKET Matrix to be an effective technology for the treatment of challenging diabetic foot ulcers,” said Eric E. Gay, Director of Biologics Marketing at Wright Medical. “We are pleased to reach this milestone publication that will help further strengthen surgeon, patient and payor confidence in our innovative technology. With this new level-1 evidence proving effectiveness, we believe the impact that GRAFTJACKET Matrix can have on patients’ lives, as well as overall healthcare costs, can now be more fully-realized.” The company’s GRAFTJACKET Matrix is a processed three-dimensional human dermal tissue matrix that allows the body to rebuild areas of deficient tissue. After this regenerative matrix is applied to a wound, the body’s natural repair process revascularizes and repopulates the GRAFTJACKET Matrix with its own cells, gradually converting the graft into the patient’s own living tissue.